<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03629405</url>
  </required_header>
  <id_info>
    <org_study_id>PH4G-04/2016</org_study_id>
    <nct_id>NCT03629405</nct_id>
  </id_info>
  <brief_title>Assessment of the Efficacy and Barrier Protection of Two Cosmetic Products</brief_title>
  <official_title>Assessment of the Long-Term Efficacy and Barrier Protection of Two Skin Care Products</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr. August Wolff GmbH &amp; Co. KG Arzneimittel</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>proDERM Institut für Angewandte Dermatologische Forschung GmbH</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Microscopy Services Dähnhardt GmbH</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Dr. August Wolff GmbH &amp; Co. KG Arzneimittel</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study was to assess the long-term efficacy and barrier protection properties
      of two cosmetic products on the volar forearms of 20 elderly subjects after four weeks of
      treatment compared to two untreated test areas.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 11, 2016</start_date>
  <completion_date type="Actual">September 9, 2016</completion_date>
  <primary_completion_date type="Actual">September 9, 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Skin pH</measure>
    <time_frame>baseline, Day 29, Day 30</time_frame>
    <description>Change from baseline at Day 29 and Day 30 of Skin pH Units assessed by pH-meter</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Transepidermal Water Loss</measure>
    <time_frame>baseline, Day 29, Day 30</time_frame>
    <description>Change from baseline at Day 29 and Day 30 of Transepidermal Water Loss (g/m2/h) assessed by Tewameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Skin Hydration</measure>
    <time_frame>baseline, Day 29, Day 30</time_frame>
    <description>Change from baseline at Day 29 and Day 30 of Skin Hydration Arbitrary Units assessed by Corneometer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intercellular lipid lamellae lenght (nm ICLL/1000 nm2 ICS)</measure>
    <time_frame>baseline, Day 29, Day 30</time_frame>
    <description>Change from baseline at Day 29 and Day 30 of stratum corneum assessed by transmission electron microscopy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lipid Analysis ((concentration of : Cholesterol (µg/slide), FFA (µg/slide), Ceramide EOS (µg/slide), Ceramide NP (µg/slide), Ceramide NH (µg/slide))</measure>
    <time_frame>baseline, Day 29, Day 30</time_frame>
    <description>Change from baseline at Day 29 and Day 30 of corneocyte layer area assessed from the TEM data</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Aged Skin</condition>
  <arm_group>
    <arm_group_label>A - Negative control (untreated) for product C</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>On the forearms four test areas were located, which were labeled from A-D. Test area A contralateral to product C</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B - Negative control (untreated) for product D</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>On the forearms four test areas were located, which were labeled from A-D. Test area B contralateral to product D</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C - Cosmetic Product WO 3741 with pH 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>On the forearms four test areas were located, which were labeled from A-D. Test area C on the same arm like product D.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>D - Cosmetic Product WO 4081-1 with pH 5.8</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>On the forearms four test areas were located, which were labeled from A-D.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>C - pH 4 Cosmetic Product WO 3741</intervention_name>
    <description>Application of the product on the pre-defined skin area on the forearms twice daily for four weeks</description>
    <arm_group_label>C - Cosmetic Product WO 3741 with pH 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>D - pH 5.8 Cosmetic Product WO 4081-1</intervention_name>
    <description>Application of the product on the pre-defined skin area on the forearms twice daily for four weeks</description>
    <arm_group_label>D - Cosmetic Product WO 4081-1 with pH 5.8</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written Informed Consent to participate in the study

          -  Willingness to actively participate in the study and to come to the scheduled visits

          -  Female and male (at least 30% male subjects)

          -  From 50 to 75 years of age, equally distributed

        Exclusion Criteria:

          -  Female subjects: Pregnancy or lactation

          -  Drug addicts, alcoholics

          -  AIDS or infectious hepatitis if known to the subjects

          -  Conditions which exclude a participation or might influence the test reaction/
             evaluation

          -  Participation or being in the waiting period after participation in similar cosmetic
             and/or pharmaceutical studies

          -  Active skin disease at the test area

          -  One of the following serious illnesses that might require regular systemic medication:
             insulin-dependent diabetes

          -  Moles, tattoos, scars, irritated skin, hairs, etc. at the test area that could
             influence the Investigation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Prof. Klaus-Peter Wilhelm, MD</last_name>
    <role>Study Director</role>
    <affiliation>proDERM Institute for Applied Dermatological Research, Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>proDERM Institute for Applied Dermatological Research</name>
      <address>
        <city>Schenefeld</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>August 10, 2018</study_first_submitted>
  <study_first_submitted_qc>August 10, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 14, 2018</study_first_posted>
  <last_update_submitted>August 10, 2018</last_update_submitted>
  <last_update_submitted_qc>August 10, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 14, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>pH of the skin</keyword>
  <keyword>SDS</keyword>
  <keyword>Lipbarvis</keyword>
  <keyword>TEWL</keyword>
  <keyword>Skin hydration</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

